The Australian paralysis tick occupies a unique and feared position among the country’s parasites. Found along the humid eastern seaboard, I. holocyclus feeds on a wide range of mammals, and its adult females secrete a potent neurotoxin known as holocyclotoxin while taking a blood meal. In young calves and other naïve animals that have not developed tolerance, this toxin can cause progressive, ascending paralysis that may prove fatal if the tick is not found and removed. For livestock producers, the tick represents both an animal welfare hazard and an economic burden, particularly in dairy and beef operations where calves graze on tick-infested pasture during the warmer months when tick activity peaks.

Existing control options leave a significant gap. Acaricide treatments used against other cattle parasites, such as the cattle tick Rhipicephalus australis, are not always reliably effective against I. holocyclus, and their persistence can be too short to cover the weeks during which calves remain vulnerable. Products registered specifically for paralysis tick control in cattle are limited, and no pour-on formulation had been approved for this purpose in Australia. Pour-on applications are attractive in practice because they avoid the stress and labor of injectable handling regimes or labor-intensive individual tick searches across large herds. Against this backdrop, fluralaner, a member of the isoxazoline class of ectoparasiticides, appeared to be a promising candidate. Isoxazolines act on the nervous systems of arthropods by blocking ligand-gated chloride channels, producing paralysis and death of the parasite, and fluralaner has already demonstrated efficacy against I. holocyclus in dogs and cats. The compound is characterized by systemic distribution and prolonged persistence in the host, which is precisely the profile needed for a long-acting tick control product.

To test the formulation rigorously, the researchers designed two randomised, controlled and blinded studies using a total of 40 healthy male dairy calves, with 20 calves allocated to each study. Within each study, calves were randomly assigned either to an untreated control group or to a fluralaner-treated group, with ten animals in each arm. On Day 0, treated calves received a single topical application of the fluralaner pour-on solution at a minimum dose of 2.5 milligrams per kilogram of body weight, applied along the topline in the manner typical of commercial pour-on products. To establish a pre-existing infestation that would allow the therapeutic effect to be measured, calves were experimentally infested with unfed adult female I. holocyclus ticks on Day −1, one day before treatment. Study 1 used an infestation challenge of ten ticks per calf, while Study 2 used fifteen ticks per calf, providing a slightly heavier parasite burden in the second trial.

The assessment protocol distinguished carefully between therapeutic and persistent efficacy. Therapeutic efficacy, the ability of the treatment to kill ticks already on the animal, was evaluated 48 hours after treatment by comparing live tick counts between treated and control calves. Ticks were first assessed in situ at 24 hours post-treatment, and then counted and removed at 48 hours. Persistent efficacy, the ability of the treatment to protect against new infestations, was assessed by re-infesting all calves weekly with fresh adult female ticks for up to six weeks after treatment. Following each re-infestation, ticks were assessed in situ at 48 hours and then counted and removed at 72 hours, with live tick counts in treated calves compared against those in untreated controls at every time point. This weekly challenge design is demanding, because it tests whether the drug remains at acaricidal concentrations in the skin and blood long after a single application.

The results were striking, particularly for persistent protection. Against the pre-existing infestation, therapeutic efficacy measured at 48 hours post-treatment was 95.5 percent in Study 1 and 69.1 percent in Study 2, indicating that the pour-on formulation killed the substantial majority of ticks already feeding on the treated calves, though the effect against established infestations was somewhat more variable in the second study. The persistent efficacy, however, was remarkable: at 72 hours after each weekly re-infestation, efficacy remained at 100 percent throughout the assessment period in Study 1, and ranged from 98.6 to 100 percent in Study 2. In practical terms, this means that for several weeks after a single application, virtually no tick that attempted to feed on a treated calf survived long enough to complete a blood meal, which is the critical threshold for preventing toxin delivery.

Statistical analysis reinforced the biological picture. Fluralaner-treated calves carried significantly fewer live ticks than untreated controls at all 72-hour assessments through to Week 4, with P values of 0.002 or lower. Beyond Week 4, efficacy declined below the 95 percent benchmark in both studies, marking the practical limit of protection from a single dose under the conditions of these trials. The authors therefore concluded that a single topical administration of the fluralaner pour-on solution provided control of existing I. holocyclus infestations and sustained protection against re-infestation for 28 days in calves under controlled experimental conditions. The four-week window aligns well with common livestock management cycles, suggesting that a monthly treatment schedule during the tick season could keep calves protected through the period of peak risk.

Safety and tolerability, always central considerations for a new use of a veterinary medicine, were also assessed. The treatment was well tolerated across all 20 treated calves, with only one mild, localized skin reaction observed at the application site. No other adverse effects were reported. The studies were conducted with animal ethics approval from the New South Wales Department of Primary Industries Secretary’s Animal Care and Ethics Committee for Study 1 and the Wongaburra Research Centre Animal Ethics Committee for Study 2, and under an Australian Pesticides and Veterinary Medicines Authority permit for small-scale trials with agricultural and veterinary chemicals. The statistical analysis was performed by Fangshi Sun of Merck Animal Health, and the studies were funded by Merck Animal Health, with both authors employed by MSD Animal Health Australia, a disclosure that readers should weigh when interpreting the uniformly positive results.

The significance of the work extends beyond the specific numbers. A pour-on isoxazoline product with a month-long duration of action against paralysis ticks would address several practical limitations of current approaches. It would reduce the frequency of handling, lower the labor required for tick surveillance in susceptible calves, and provide a margin of safety against the toxin that individual tick searches cannot guarantee, since a single engorging female can paralyze a small calf. The systemic mode of action also means protection does not depend on the tick contacting a treated patch of skin, as is the case with some repellent or topical products. Because fluralaner has an established track record against I. holocyclus in companion animal medicine, the class itself is well characterized, although dose rates, formulations and withdrawal considerations for cattle differ substantially from those for dogs and cats.

Important caveats remain before the findings translate into on-farm practice. The trials were conducted under controlled experimental conditions with fixed infestation pressures of laboratory-placed adult female ticks, which do not fully reproduce the variable exposure, weather, and mixed tick populations of commercial pastures. Efficacy against established infestations was lower in the heavier-challenge study, and protection fell below 95 percent after four weeks, so treatment intervals would need careful management. Most importantly, the authors explicitly state that at the time of publication, paralysis tick control is not an approved indication on the Australian APVMA registration of the fluralaner pour-on solution for cattle, meaning veterinarians and producers must await regulatory action before the product can be used for this purpose. Nevertheless, the study provides a robust evidence base for that next step, and it will be watched closely by producers in eastern Australia, where each tick season brings the risk of losing calves to one of the world’s most potent natural toxins.

Subject of Research: Efficacy of a fluralaner pour-on acaricide against experimental Ixodes holocyclus infestations in calves

Article Title: Efficacy of a single treatment of a fluralaner pour-on solution for cattle (Exzolt) against experimental infestations of Ixodes holocyclus on calves

Article References: de Asis, E., & Fisara, P. (2026). Efficacy of a single treatment of a fluralaner pour-on solution for cattle (Exzolt) against experimental infestations of Ixodes holocyclus on calves. Parasites & Vectors. https://doi.org/10.1186/s13071-026-07636-2

Image Credits: AI Generated

DOI: 10.1186/s13071-026-07636-2

Keywords: Australian paralysis tick, Ixodes holocyclus, fluralaner, isoxazoline, calves, cattle, acaricide, pour-on treatment, holocyclotoxin, Parasites & Vectors, tick control, veterinary parasitology

The logic behind the approach rests on the peculiar ecology of Lyme disease in the northeastern United States. The blacklegged tick, Ixodes scapularis, passes the bacterium Borrelia burgdorferi sensu stricto through its life stages, but the pathogen’s persistence in a given landscape depends heavily on one particular host: the white-footed mouse, Peromyscus leucopus. These abundant rodents serve as the principal natural reservoir of the spirochete, and larval ticks that feed on infected mice are far more likely to acquire the bacterium than larvae feeding on deer, birds, or other mammals. When those larvae molt into nymphs the following year, the infected nymphs become the primary threat to humans, delivering the bite that transmits Lyme disease in the vast majority of cases.

Interrupting the cycle at the mouse-tick interface has therefore long been an attractive target for researchers. Earlier laboratory and simulated field studies had already demonstrated that a bait containing just 0.005 percent fipronil could systemically control Ixodes scapularis ticks parasitizing treated white-footed mice. Fipronil, the same active ingredient found in some companion-animal flea and tick products, works systemically: after a mouse ingests the bait, the compound and its metabolites circulate in the animal’s blood, and ticks that attach and begin feeding are killed before they can complete their blood meal. The question the Connecticut study set out to answer was whether that laboratory promise would survive contact with real backyards, real weather, and real wildlife.

Between 2022 and 2024, the research team deployed reusable rodent bait stations on residential properties during the period when blacklegged ticks are active in their nymphal and larval stages, roughly May through August. The stations dispensed the fipronil-treated bait to free-ranging mice, and the team monitored consumption, replenishing bait as needed to keep the system running through each season. On average, each property received 4.9 kilograms of bait per year, which translates to approximately 247 milligrams of fipronil—a remarkably small total quantity of active ingredient distributed across an entire property over an entire season.

To confirm that the mice were actually being exposed to the compound, the researchers captured white-footed mice during the larval season each year on both treated and untreated control properties and analyzed their blood plasma. The results were striking: fipronil sulfone, a metabolite that serves as a marker of exposure, was detectable in 100 percent of plasma samples analyzed in both 2022 and 2023, and in 83.3 percent of samples in 2024. In other words, the bait stations were doing their job, delivering the active ingredient to the target animals with high consistency even under fully natural field conditions.

The effect on the ticks themselves was even more impressive. On treated properties, the number of larvae parasitizing captured mice fell by up to 84.2 percent compared with control properties, and the number of larvae that successfully engorged—those that managed to complete a blood meal, which is the critical step for both tick survival and pathogen acquisition—dropped by up to 92.5 percent. A larval tick that fails to engorge on a mouse not only fails to acquire Borrelia from that mouse; it also faces greatly reduced odds of surviving to molt into the next life stage. The bait, in effect, turned the most important host in the Lyme disease system into a lethal trap for its parasites.

The benefits extended to the pathogen as well. Molecular assays used to detect Borrelia burgdorferi infection in the captured mice showed that infection prevalence in white-footed mice on treated properties was significantly reduced by up to 34.1 percent relative to controls. That reduction matters because fewer infected mice means fewer larval ticks acquiring the spirochete, which in principle should mean fewer infected nymphs questing for human blood the following spring. The study thus demonstrated a measurable dent in the reservoir competence of the local mouse population, achieved not by reducing mouse numbers but by breaking the tick-mouse transmission loop.

The picture was more nuanced, however, when the researchers turned to the stage of the tick life cycle that matters most for human health. Drag sampling and flagging during the nymphal seasons were used to estimate the abundance of host-seeking nymphs on the properties, and molecular testing assessed how many of those nymphs carried Borrelia. While both nymph density and nymphal infection showed reductions on treated properties, neither difference reached statistical significance compared with the control sites. The authors suggest that the bait application rate during the larval season may need to be increased to push these downstream effects over the threshold of detectability—a reminder that intervening at one link of a complex transmission chain does not automatically translate into reduced risk at every other link.

That caveat aside, the study represents one of the most thorough field evaluations to date of a systemic acaricide bait aimed at the wildlife reservoir of Lyme disease. Its design—multi-year, property-level, with matched controls, bait-consumption monitoring, pharmacokinetic confirmation, and molecular pathogen testing on both rodents and questing ticks—addresses many of the weaknesses that have plagued earlier tick-control trials. The extremely low dose of active ingredient involved also raises the prospect of an environmentally targeted intervention: rather than broadcasting insecticides across vegetation, the treatment is delivered only to the small mammals that seek out the bait stations, and only in quantities measured in hundreds of milligrams per property per year.

The researchers, based at Genesis Laboratories in Colorado and the Connecticut Agricultural Experiment Station, were supported by a contract with the United States Centers for Disease Control and Prevention, and the work benefited from molecular detection assistance from CDC scientists. They emphasize that additional field studies are needed to confirm the findings and to explore what large-scale treatment across neighborhoods or landscapes might achieve, since tick populations on untreated properties can continually seed treated areas. Still, the core result stands: a bait box, a few hundred milligrams of fipronil, and the natural foraging behavior of white-footed mice were enough to strip the vast majority of larval ticks from the animals that sustain Lyme disease in the northeastern United States. As integrated tick management strategies evolve, the humble mouse bait station may prove to be one of the most quietly powerful tools in the fight against America’s most common vector-borne disease.

Subject of Research: Field efficacy of low-dose fipronil bait for controlling blacklegged ticks on white-footed mice and reducing Lyme disease transmission

Article Title: Efficacy of a low-dose fipronil bait in controlling blacklegged tick (Ixodes scapularis) larvae parasitizing white-footed mice (Peromyscus leucopus) under field conditions in the northeastern United States

Article References: Poché, D. M., Williams, S. C., Linske, M. A., & Poché, R. M. (2026). Efficacy of a low-dose fipronil bait in controlling blacklegged tick (Ixodes scapularis) larvae parasitizing white-footed mice (Peromyscus leucopus) under field conditions in the northeastern United States. Parasites & Vectors, 19(1), Article 423. https://doi.org/10.1186/s13071-026-07676-8

Image Credits: AI Generated

DOI: 10.1186/s13071-026-07676-8

Keywords: Lyme disease, Ixodes scapularis, Peromyscus leucopus, fipronil, tick control, Borrelia burgdorferi, vector-borne disease, systemic acaricide, bait stations, integrated tick management, Connecticut, public health

The rationale for targeting mucins rests on their central role in tick biology. Mucins are heavily glycosylated proteins that, in ticks, contribute to the formation of the cement cone that anchors the mouthparts into the host skin during feeding, help modulate the host immune response at the bite site, and participate in assembling the peritrophic membrane that lines the tick gut and protects it from ingested blood and microbes. Because these functions are essential to feeding and survival, proteins involved in them are attractive vulnerabilities: antibodies circulating in the host’s blood would be ingested by the tick and could interfere with these processes from within the parasite.

Before committing to laboratory production, the team characterized Mucin-6 using bioinformatic tools. The predictions indicated a hydrophilic but intrinsically unstable protein with a molecular mass of 24.9 kilodaltons after removal of its signal peptide, the short N-terminal sequence that normally directs secretion. Importantly for vaccine design, the sequence was predicted to be rich in linear B-cell epitopes, the short stretches of amino acids that antibodies can recognize on a denatured or soluble protein. Abundant epitopes increase the likelihood that vaccination will elicit a robust and specific humoral response, which is the arm of immunity most relevant for an antigen that will be encountered by the tick through a blood meal.

To confirm that the gene is biologically relevant throughout the tick life cycle, the researchers used quantitative PCR to measure Mucin-6 expression across developmental stages and feeding states. The gene was transcribed at every stage examined, from larva to adult, with significantly higher expression in eggs. This broad and consistent expression profile matters for vaccine utility: an antigen expressed only in a narrow stage or feeding condition would leave windows in which the parasite is unprotected, whereas a constitutively expressed protein offers a target throughout the tick’s interaction with the vaccinated host.

With the sequence validated, the team moved to recombinant production. The Mucin-6 coding sequence was cloned into the pET28a expression vector and transformed into BL21(DE3) Escherichia coli, a standard laboratory strain engineered for high-level protein expression under T7 promoter control. On induction, the recombinant protein accumulated in inclusion bodies, the dense aggregates of misfolded protein that bacteria often form when expressing foreign or disulfide-rich proteins. The researchers recovered the protein from these bodies, renatured it to restore a soluble conformation, and purified it using nickel-nitrilotriacetic acid affinity chromatography, which exploits the histidine tag encoded by the pET28a vector. On SDS-PAGE, the purified recombinant Mucin-6 migrated at approximately 41 kilodaltons, larger than the predicted 24.9 kilodaltons of the mature protein, a discrepancy consistent with the tag and the anomalous electrophoretic behavior typical of mucin-like, compositionally biased proteins.

The immunization trial used six New Zealand White rabbits randomly assigned to a vaccinated group of three and a phosphate-buffered saline control group of three. Each vaccinated rabbit received 500 micrograms of recombinant Mucin-6 formulated with Freund’s adjuvant in three subcutaneous injections spaced 14 days apart. Enzyme-linked immunosorbent assays tracked the antibody response, revealing titers that reached 1:512,000 by day 35, an exceptionally high level indicating strong recognition of the recombinant antigen. Fourteen days after the final booster, the researchers challenged each rabbit with 30 adult ticks, 15 males and 15 females, and measured the parameters that define tick vaccine efficacy: engorgement weight, egg mass, blood-feeding duration and egg-hatching rate.

The results showed a consistent, statistically significant burden on the parasites. Ticks that fed on immunized rabbits had engorged body weights reduced by 13.6 percent and egg masses reduced by 14.7 percent compared with ticks fed on control rabbits, both differences significant at P less than 0.05. Blood-feeding duration was prolonged by 8.3 percent, suggesting that antibodies disrupted the efficiency of feeding, forcing ticks to remain attached longer to obtain a full blood meal. Combining the effects on tick weight and fecundity, the authors calculated an overall vaccine efficacy of 26.3 percent. While modest compared with the best commercial anti-tick formulations, this figure represents a meaningful proof of concept for a single antigen tested in its first host species.

A critical question for any recombinant antigen is whether antibodies raised against the laboratory-produced protein also recognize the native version in the parasite. The team addressed this by western blot, incubating tick lysates with serum from the immunized rabbits. The anti-rMucin-6 serum bound native Mucin-6 in tick extracts, confirming that the recombinant protein preserved epitopes present in the authentic tick protein and that the antibodies generated in the vaccinated animals could, in principle, engage their target during a natural blood meal. This cross-recognition underpins the observed phenotypic effects and strengthens the case that Mucin-6, rather than an artifact of immunization, is the operative antigen.

The study sits within a broader effort to develop anti-tick vaccines that reduce both parasite loads and pathogen transmission without the drawbacks of chemical acaricides. The only commercially available tick vaccine, based on the gut antigen Bm86 against Rhipicephalus microplus, demonstrated decades ago that vaccinating the host can starve and sterilize ticks from within, but its efficacy varies across tick species and regions, driving the search for new antigens. Secreted proteins such as mucins, which are exposed to host antibodies in the ingested blood and are functionally indispensable, form a promising class of candidates. The Hainan team’s work adds Mucin-6 to this pipeline and demonstrates a complete workflow, from epitope prediction and expression profiling through prokaryotic production and a controlled animal challenge.

Limitations remain before Mucin-6 could approach practical deployment. The trial involved a small number of animals, a single antigen and a single host species, and Freund’s adjuvant is unsuitable for veterinary or human use, so future work would need to test the antigen with licensed adjuvants, in larger cohorts, and ideally in combination with other antigens to push efficacy higher. The authors, led by corresponding author Qingfeng Guan with co-first authors Jie Chen and Yongchuan Zhu, conclude that Mucin-6 merits further evaluation as a candidate vaccine antigen against R. linnaei. Given that tick-borne diseases continue to expand their geographic range with changing climates and livestock movements, even incremental gains from antigen discovery of this kind carry substantial implications for animal health and the economics of tick control.

Subject of Research: Evaluation of the tick protein Mucin-6 from Rhipicephalus linnaei as a recombinant anti-tick vaccine antigen

Article Title: Prokaryotic expression and vaccine potential of Mucin-6 from Rhipicephalus linnaei

Article References: Chen, J., Zhu, Y., Zhao, J., Wang, J., Han, Q., & Guan, Q. (2026). Prokaryotic expression and vaccine potential of Mucin-6 from Rhipicephalus linnaei. Parasites & Vectors. https://doi.org/10.1186/s13071-026-07675-9

Image Credits: AI Generated

DOI: 10.1186/s13071-026-07675-9

Keywords: Rhipicephalus linnaei, Mucin-6, anti-tick vaccine, recombinant protein, prokaryotic expression, vaccine efficacy, tick control, humoral immunity, B-cell epitopes, Parasites & Vectors, livestock health, vector biology